1. Home
  2. CAPR vs JMSB Comparison

CAPR vs JMSB Comparison

Compare CAPR & JMSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • JMSB
  • Stock Information
  • Founded
  • CAPR 2005
  • JMSB 2005
  • Country
  • CAPR United States
  • JMSB United States
  • Employees
  • CAPR N/A
  • JMSB N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • JMSB Major Banks
  • Sector
  • CAPR Health Care
  • JMSB Finance
  • Exchange
  • CAPR Nasdaq
  • JMSB Nasdaq
  • Market Cap
  • CAPR 324.6M
  • JMSB 270.0M
  • IPO Year
  • CAPR N/A
  • JMSB N/A
  • Fundamental
  • Price
  • CAPR $6.36
  • JMSB $20.08
  • Analyst Decision
  • CAPR Strong Buy
  • JMSB Buy
  • Analyst Count
  • CAPR 8
  • JMSB 2
  • Target Price
  • CAPR $24.75
  • JMSB $22.50
  • AVG Volume (30 Days)
  • CAPR 1.2M
  • JMSB 14.0K
  • Earning Date
  • CAPR 11-12-2025
  • JMSB 10-22-2025
  • Dividend Yield
  • CAPR N/A
  • JMSB 1.50%
  • EPS Growth
  • CAPR N/A
  • JMSB 688.28
  • EPS
  • CAPR N/A
  • JMSB 1.32
  • Revenue
  • CAPR $13,392,150.00
  • JMSB $56,750,000.00
  • Revenue This Year
  • CAPR N/A
  • JMSB $18.36
  • Revenue Next Year
  • CAPR $6,061.53
  • JMSB $12.36
  • P/E Ratio
  • CAPR N/A
  • JMSB $15.20
  • Revenue Growth
  • CAPR N/A
  • JMSB 59.00
  • 52 Week Low
  • CAPR $4.05
  • JMSB $13.81
  • 52 Week High
  • CAPR $23.40
  • JMSB $26.52
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 42.32
  • JMSB 53.95
  • Support Level
  • CAPR $6.05
  • JMSB $19.57
  • Resistance Level
  • CAPR $6.62
  • JMSB $20.85
  • Average True Range (ATR)
  • CAPR 0.39
  • JMSB 0.50
  • MACD
  • CAPR 0.05
  • JMSB 0.03
  • Stochastic Oscillator
  • CAPR 47.89
  • JMSB 53.61

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About JMSB John Marshall Bancorp Inc.

John Marshall Bancorp Inc is a bank holding company. Through its banking subsidiary, it offers banking products and financial services to small to medium-sized businesses, professional corporations, non-profits, and individuals. The products and services offered by the company include commercial checking, savings, and money market accounts, certificates of deposit, treasury and cash management services, commercial and industrial loans, commercial real estate loans, residential and commercial construction and development loans, online banking, and mobile banking. The firm serves local businesses, professionals, individuals, and families throughout the Washington, D.C. metropolitan area.

Share on Social Networks: